Manchester Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Manchester Capital Management's REGN Position: Q2 2026 in Review
Manchester Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 2.2% in Q2 2026, buying an estimated $681 and bringing the position to 47 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #616.
Manchester Capital Management first reported a position in REGN in Q2 2013 and has held it in 23 quarters since. The position peaked at $173K in Q2 2013. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Manchester Capital Management held 47 shares of Regeneron Pharmaceuticals worth $29.3K as of Q2 2026.
- Manchester Capital Management bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
- Regeneron Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #616 holding.
- Manchester Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 23 quarters since.
- Manchester Capital Management's Regeneron Pharmaceuticals position peaked at $173K in Q2 2013.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.